GLCYEMIC LEVELS IN CHILDREN OF 6-18 YEARS AGE GROUP USING INHALED CORTICOSTEROIDS FOR ASTHMA
Not Applicable
- Conditions
- Health Condition 1: J459- Other and unspecified asthma
- Registration Number
- CTRI/2020/07/026686
- Lead Sponsor
- Dr Anisha Susan Sojan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a)Children aged 6 years to 18 years admitted in the Department of Pediatrics and diagnosed to have Persistent asthma (as per GINA guidelines) and started on inhaled corticosteroids will be enrolled.
b)The compliance to ICS will be checked at follow up. (Compliance will be considered good if the child takes the inhaler as prescribed on at least 20/30 days in a month, and the inhaler meter reading will also be checked.)
Exclusion Criteria
a)Children having co-existing cardiac disease/Diabetes Mellitus/Hypothyroidism.
b)Children who are already on systemic corticosteroids/previously used inhalational corticosteroids
c)Children whose parents refuse to participate in the study.
d)Children younger than 6 years
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the HbA1c levels of children aged 6-18 years using ICS for asthma at baseline and after 6months of ICS useTimepoint: From obtaining IEC clearance to Aug 2021 <br/ ><br>Case Enrollment : Dec 2019 to Feb 2021 <br/ ><br>Follow up period : June 2020 to Aug 2021 <br/ ><br>
- Secondary Outcome Measures
Name Time Method To study the correlation between doses of Inhaled Corticosteroids (Low dose, Medium dose, High Dose according to GINA guidelines) and HbA1c level <br/ ><br>To study Clinical profile of children 6-18 years with Persistent Asthma <br/ ><br>Timepoint: From obtaining IEC clearance to Aug 2021 <br/ ><br>Case Enrollment : Dec 2019 to Feb 2021 <br/ ><br>Follow up period : June 2020 to Aug 2021 <br/ ><br>